Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Translate Bio
Founder CEO Sanjay Singh tells Scrip about Gennova Biopharma's preliminary talks with investors looking to grab a piece of the action post approval of its mRNA vaccine against COVID-19. As the company considers use of the technology in making vaccines against cancer and infectious diseases, it will also expand manufacturing
Speaking at BIO-Europe Spring, three leaders of platform life sciences companies offer advice on their scalable and lower risk business models that support innovation within partner biopharma companies.
Sanofi's executive vice-president and head of vaccines, Thomas Triomphe, outlines in an interview with Scrip the role of evolutive vaccine facilities that are adaptable to new platforms like mRNA, a core cog expected to drive the French group’s innovation ambitions. Finding a sustainable ‘sweet spot’ when it comes to regulatory speed post the pandemic is among the other topics the executive touched upon.
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- RaNA Therapeutics Inc.